Samsung Biologics has taken part for the first time in the American Association for Cancer Research (AACR), one of the world’s largest cancer research conferences, to promote the competitiveness of its contract research, development and manufacturing (CRDMO) business.

Samsung Biologics stated on the 20th that it is participating in the AACR being held in San Diego, California, and is actively promoting its integrated bio service capabilities.

AACR is a large-scale conference that brings together more than 20,000 researchers and pharmaceutical and biotech industry representatives from over 140 countries, and is regarded as a key venue for identifying the latest trends in cancer research.

Samsung Biologics explained that at this year’s event it is focusing on expanding contact points with clients around its CRDMO services, which encompass contract research (CRO), contract development (CDO), and contract manufacturing (CMO). In particular, the company plans to build long-term client relationships through an “early lock-in” strategy that initiates collaboration at the early new drug development stage and continues through to commercial production.

The company reported that it showcased its technological capabilities on site through various presentations and exhibits. On the 21st, its organoid sales director is scheduled to give a presentation titled “Samsung Organoid: Enhancing Clinical Relevance in Oncology Drug Development.” The presentation will highlight how organoid models with high patient similarity precisely reproduce actual genetic characteristics and drug responses, demonstrating a strong correlation with clinical outcomes. In addition, a poster session will be held on the therapeutic efficiency and manufacturing competitiveness of its bispecific antibody platform “S-DUAL.”

Samsung Biologics has recently been rapidly expanding its business scope. In 2025, it launched organoid-based CRO services, extending its business into the research stage, and in 2026 it internalized master cell bank production and vector generation, strengthening its CDO capabilities. Through this, the company is building an integrated service that covers the entire process from discovery of new drug candidates to commercialization.

Jung Hyung-nam, head of the Bio Research Center, said, “By providing CRO and CDO services from the early development stage, the company will establish itself as a trusted partner for clients,” adding, “We will continue to develop innovative technologies to provide customized services.”

Meanwhile, Samsung Biologics plans to expand its global contract acquisition activities by participating in the BIO International Convention this June, following its attendance at the J.P. Morgan Healthcare Conference and DCAT Week earlier this year.

Popular News